REDWOOD CITY, Calif., Dec. 7 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that results from eight studies of the company's Oncotype DX(R) breast cancer test are scheduled to be presented at the 30th Annual San Antonio Breast Cancer Symposium, taking place December 13-16, 2007. Oncotype DX is a multi-gene expression test that physicians use to predict the likelihood of recurrence and the likelihood of chemotherapy benefit for a large portion of early-stage breast cancer patients.
Following are details for each embargoed session (all times are Central
Thursday, Dec. 13, 2007, 9:15 to 9:30 a.m.
Late-Breaking oral presentation: "Prognostic and predictive value of the
21-gene Recurrence Score assay in postmenopausal, node-positive, ER
positive breast cancer.
"Presenter: Kathy S. Albain, M.D.
Thursday, Dec. 13, 2007, 5 to 7 p.m.
Poster presentation: Recurrence Score by Oncotype DX evaluated on the
primary breast tumor predicts the 2-year survival after first relapse.
Presenter: Giampaolo Bianchini, M.D.
Poster presentation: "Prospective multi-center study of the impact of the
21-gene Recurrence Score assay on patient satisfaction, anxiety and
decisional conflict for adjuvant breast cancer treatment
"Presenter: Patricia B. Mumby, Ph.D.
Friday, Dec. 14, 7 to 9 a.m.
Poster presentation: "A retrospective analysis of the impact of Oncotype
DX low Recurrence Score results on treatment decisions in a single
academic breast cancer center.
"Presenter: Hongmei Lian
|SOURCE Genomic Health, Inc.|
Copyright©2007 PR Newswire.
All rights reserved